Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ECOG-ACRIN EA8231
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- NCT06524544 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on ECOG-ACRIN EA8231 (pembrolizumab, sacituzumab govitecan and 5 more in Locally Advanced Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ECOG-ACRIN EA8231 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma
- Interventions
- Biospecimen Collection; Carboplatin; Cisplatin; Computed Tomography; Docetaxel; Gemcitabine; Magnetic Resonance Imaging; Paclitaxel; Pembrolizumab; Questionnaire Administration; Sacituzumab Govitecan
- Arms
- Arm I (TPC chemotherapy) · Active comparator
- Arm II (pembrolizumab, sacituzumab govitecan-hziy) · Experimental
- Enrollment
- 320 (estimated)
- Primary outcomes
- Overall survival (OS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Dec 2, 2025
- Primary completion
- Dec 31, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06524544 · updated Oct 5, 2026